J&J vaccine approved for emergency use in Canada

Johnson & Johnson, who has been making production headlines in the US, recently revealed that Health Canada has granted an interim order (IO) authorization for its single-shot Covid-19 vaccine, developed by J&J's Janssen Pharmaceutical Companies unit, to prevent Covid-19 in people 18 years of age and older.

This decision was based on scientific evidence, including data from the Phase III ENSEMBLE study that demonstrated the vaccine was 85% effective in preventing severe disease, and exhibited protection against Covid-19 related hospitalization and death, beginning 28 days after vaccination.

J&J envisions fulfilling the 10 million doses included in the advance purchase agreement with the government of Canada by the end of Q3.